MDM2 Inhibitor Breaks Through in Trial of Liposarcoma, Other Advanced Malignancies
MedPage Today,
Oncology/Hematology > Other Cancers Intermittent dosing dramatically reduced myelosuppression that has hindered drug class by…
Oncology/Hematology > Other Cancers Intermittent dosing dramatically reduced myelosuppression that has hindered drug class by…
Abstract Gains and losses of DNA are prevalent in cancer and emerge as a consequence of inter-related processes of replication…
Johns Hopkins Kimmel Cancer Center researchers and colleagues have identified a novel drug combination therapy that could prime…
Johns Hopkins Kimmel Cancer Center researchers and colleagues have identified a novel drug combination therapy that could prime…